Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A secondary RET mutation in the activation loop conferring resistance to vandetanib.

Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles PP, Tsuchihara K, Matsumoto S, Shimada Y, Mimaki S, Ishii G, Ichikawa H, Nagatoishi S, Tsumoto K, Okuno Y, Yoh K, McDonald NQ, Goto K.

Nat Commun. 2018 Feb 12;9(1):625. doi: 10.1038/s41467-018-02994-7.

2.

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.

Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, Mrugalla F, Alber Y, Richters A, Engel J, Leenders F, Heuckmann JM, Wolf J, Diebold J, Pall G, Peifer M, Aerts M, Gevaert K, Zahedi RP, Buettner R, Shokat KM, McDonald NQ, Kast SM, Gautschi O, Thomas RK, Sos ML.

Sci Transl Med. 2017 Jun 14;9(394). pii: eaah6144. doi: 10.1126/scitranslmed.aah6144.

3.

aPKC Inhibition by Par3 CR3 Flanking Regions Controls Substrate Access and Underpins Apical-Junctional Polarization.

Soriano EV, Ivanova ME, Fletcher G, Riou P, Knowles PP, Barnouin K, Purkiss A, Kostelecky B, Saiu P, Linch M, Elbediwy A, Kjær S, O'Reilly N, Snijders AP, Parker PJ, Thompson BJ, McDonald NQ.

Dev Cell. 2016 Aug 22;38(4):384-98. doi: 10.1016/j.devcel.2016.07.018.

4.

RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association.

Goodman KM, Kjær S, Beuron F, Knowles PP, Nawrotek A, Burns EM, Purkiss AG, George R, Santoro M, Morris EP, McDonald NQ.

Cell Rep. 2014 Sep 25;8(6):1894-1904. doi: 10.1016/j.celrep.2014.08.040. Epub 2014 Sep 18.

5.

Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes.

Kjær S, Linch M, Purkiss A, Kostelecky B, Knowles PP, Rosse C, Riou P, Soudy C, Kaye S, Patel B, Soriano E, Murray-Rust J, Barton C, Dillon C, Roffey J, Parker PJ, McDonald NQ.

Biochem J. 2013 Apr 15;451(2):329-42. doi: 10.1042/BJ20121871.

PMID:
23418854
6.

Molecular recognition of the Tes LIM2-3 domains by the actin-related protein Arp7A.

Boëda B, Knowles PP, Briggs DC, Murray-Rust J, Soriano E, Garvalov BK, McDonald NQ, Way M.

J Biol Chem. 2011 Apr 1;286(13):11543-54. doi: 10.1074/jbc.M110.171264. Epub 2011 Jan 29.

7.

Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.

Mologni L, Rostagno R, Brussolo S, Knowles PP, Kjaer S, Murray-Rust J, Rosso E, Zambon A, Scapozza L, McDonald NQ, Lucchini V, Gambacorti-Passerini C.

Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. doi: 10.1016/j.bmc.2010.01.011. Epub 2010 Jan 11.

PMID:
20117004
8.

Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor.

Kirk R, Laman H, Knowles PP, Murray-Rust J, Lomonosov M, Meziane el K, McDonald NQ.

J Biol Chem. 2008 Aug 8;283(32):22325-35. doi: 10.1074/jbc.M709900200. Epub 2008 May 20.

9.

Crystallization and preliminary X-ray diffraction analysis of vaccinia virus H1L phosphatase.

Roces L, Knowles PP, Fox G, Juanhuix J, Scaplehorn N, Way M, McDonald NQ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Mar 1;64(Pt 3):190-2. doi: 10.1107/S1744309108003680. Epub 2008 Feb 23.

10.

Redox-mediated substrate recognition by Sdp1 defines a new group of tyrosine phosphatases.

Fox GC, Shafiq M, Briggs DC, Knowles PP, Collister M, Didmon MJ, Makrantoni V, Dickinson RJ, Hanrahan S, Totty N, Stark MJ, Keyse SM, McDonald NQ.

Nature. 2007 May 24;447(7143):487-92. Epub 2007 May 9.

PMID:
17495930
11.

Structure and chemical inhibition of the RET tyrosine kinase domain.

Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibáñez CF, McDonald NQ.

J Biol Chem. 2006 Nov 3;281(44):33577-87. Epub 2006 Aug 23.

12.

The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition.

Nicastro G, Menon RP, Masino L, Knowles PP, McDonald NQ, Pastore A.

Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10493-8. Epub 2005 Jul 14.

13.

Structure of an XPF endonuclease with and without DNA suggests a model for substrate recognition.

Newman M, Murray-Rust J, Lally J, Rudolf J, Fadden A, Knowles PP, White MF, McDonald NQ.

EMBO J. 2005 Mar 9;24(5):895-905. Epub 2005 Feb 17.

14.

The dual mechanism of separase regulation by securin.

Hornig NC, Knowles PP, McDonald NQ, Uhlmann F.

Curr Biol. 2002 Jun 25;12(12):973-82.

15.

Crystallization of an intact GST-estrogen receptor hormone binding domain fusion protein.

Lally JM, Newman RH, Knowles PP, Islam S, Coffer AI, Parker M, Freemont PS.

Acta Crystallogr D Biol Crystallogr. 1998 May 1;54(Pt 3):423-6.

PMID:
9761916
16.

Divalent metal ions induce conformational change in pure, human wild-type p53 tumor suppressor protein.

Coffer AI, Knowles PP.

Biochim Biophys Acta. 1994 Dec 14;1209(2):279-85.

PMID:
7811703
17.

Biochemical characterisation of purified human wild-type p53 overexpressed in insect cells.

Chalkley GE, Knowles PP, Whitehead PC, Coffer AI.

Eur J Biochem. 1994 Apr 1;221(1):167-75.

18.

Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice.

Thorpe PE, Derbyshire EJ, Andrade SP, Press N, Knowles PP, King S, Watson GJ, Yang YC, Rao-Betté M.

Cancer Res. 1993 Jul 1;53(13):3000-7.

19.

Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.

Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Blakey DC, Newell DR.

Cancer Res. 1988 Nov 15;48(22):6396-403.

20.

Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.

Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G, et al.

Cancer Res. 1988 May 1;48(9):2610-7. Erratum in: Cancer Res 1988 Aug 15;48(16):4716.

21.

New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.

Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Knyba RE, Wawrzynczak EJ, Blakey DC.

Cancer Res. 1987 Nov 15;47(22):5924-31.

22.

Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.

Thorpe PE, Blakey DC, Brown AN, Knowles PP, Knyba RE, Wallace PM, Watson GJ, Wawrzynczak EJ.

J Natl Cancer Inst. 1987 Nov;79(5):1101-12.

PMID:
2890786
24.
25.

Hepatotoxicity of immunotoxins made with saporin, a ribosome-inactivating protein from Saponaria officinalis.

Stirpe F, Derenzini M, Barbieri L, Farabegoli F, Brown AN, Knowles PP, Thorpe PE.

Virchows Arch B Cell Pathol Incl Mol Pathol. 1987;53(5):259-71.

PMID:
2889289
26.

Purification of ricin A1, A2, and B chains and characterization of their toxicity.

Fulton RJ, Blakey DC, Knowles PP, Uhr JW, Thorpe PE, Vitetta ES.

J Biol Chem. 1986 Apr 25;261(12):5314-9.

Supplemental Content

Loading ...
Support Center